Alexis Parazo
Adult Health · Pasadena, CANPI 1629734777
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,987 of the $5,608 with a category attached, or 88.9%. It is spread thinly across 42 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,246 and has fallen 92.9% since, to $301 in 2025. Among adult health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$751
- Astellas Pharma US Inc$610
- Incyte Corporation$472
- Merck$428
- Johnson & Johnson$385
- Sobi, Inc$256
- plus $3K from 36 others
What the payments were for
- Food & beverage$4,98789%
- Education$62111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,608 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 12 | $188,893 |
| EliquisApixaban | 12 | $8,002 |
| Letrozole | 41 | $579 |
| Anastrozole | 16 | $533 |
| Hydroxyurea | 17 | $456 |
| Alendronate Sodium | 40 | $271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $751 | $188,89312 claims |
| PfizerEliquis | $209 | $8,00212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.
Other adult health in Pasadena
- Jackie HuangPasadena$19K
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.